logo

For the Inventor, By the Inventor

Wallingford, CT, United States of America

David J Carini

This inventor holds 16 USPTO granted patents and 5 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, Bristol-Myers Squibb Pharma Company, Dupont Pharmaceuticals Company. Active years: 2001-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David J Carini. Retrieved from https://idiyas.com/inventor/david-j-carini-vlh511en

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16

% Patents Active = 93.8

 

Average Co-Inventor Count = 3.9

ph-index = 7

Forward Citations = 218(Granted Patents)


Location History:

  • Willmington, DE (US) (2002)
  • Wilmington, DE (US) (2001 - 2005)
  • Wallingford, CT (US) (2005 - 2012)
  • Clarendon, VT (US) (2016)

Company Filing History:

goldMedal9 out of 3,745 
 
Bristol-Myers Squibb Compnay
 patents
silverMedal5 out of 234 
 
Bristol-Myers Squibb Pharma Company
 patents
bronzeMedal1 out of 106 
 
Dupont Pharmaceuticals Company
 patents
4. 1 out of 45 
 
Viiv Healthcare UK (No.5) Limited
 patents

Years Active: 2001-2016

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 9505752 - Piperidine amide derivatives as HIV attachment inhibitors (2016-11-29),
2. 8242124 - Diketopiperidine derivatives as HIV attachment inhibitors (2012-08-14),
3. 8124615 - Diketo substituted pyrrolo[2,3-C]pyridines (2012-02-28),
4. 7960406 - Diketo substituted pyrrolo[2,3-c] pyridines (2011-06-14),
5. 7807676 - Diketo-Piperazine and Piperidine derivatives as antiviral agents (2010-10-05),
6. 7807671 - Diketo-piperazine and piperidine derivatives as antiviral agents (2010-10-05),
7. 7772183 - Hepatitis C virus inhibitors (2010-08-10),
8. 7659281 - HMG-CoA reductase inhibitors (2010-02-09),
9. 7250435 - Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents (2007-07-31),
10. 7173004 - Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus (2007-02-06),
11. 6943170 - N-cycloalkylglycines as HIV protease inhibitors (2005-09-13),
12. 6849631 - Semicarbazides and their uses (2005-02-01),
13. 6593356 - Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents (2003-07-15),
14. 6413957 - Methods of inhibiting cell proliferation using indeno [1,2-c]pyrazol-4-ones (2002-07-02),
15. 6407103 - Indeno [1,2-c] pyrazol-4-ones and their uses (2002-06-18),

Title: David J Carini: Innovator in HIV Research

Introduction

David J Carini is a notable inventor based in Wallingford, CT (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds aimed at combating HIV. With a total of 16 patents to his name, Carini's work has had a profound impact on antiviral research.

Latest Patents

Among his latest patents, Carini has developed piperidine amide derivatives that serve as HIV attachment inhibitors. These compounds, which include pharmaceutically acceptable salts, are designed to inhibit the attachment of HIV to host cells. Additionally, he has worked on diketopiperidine derivatives that possess unique antiviral properties. These compounds are particularly useful for the treatment of HIV and AIDS, showcasing his commitment to addressing critical health challenges.

Career Highlights

Throughout his career, Carini has been associated with prominent companies such as Bristol-Myers Squibb Company and Bristol-Myers Squibb Pharma Company. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Tao Wang and Zhongxing Zhang. Their collaborative efforts have further advanced the research and development of innovative antiviral therapies.

Conclusion

David J Carini's contributions to HIV research through his patents and collaborations highlight his role as a key innovator in the pharmaceutical industry. His work continues to inspire advancements in the fight against viral infections.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…